The effects of mGlu7 receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains

Behavioural Pharmacology

Volumn 24, Issue 2, 2013, Pages 105-113

  O'Connor, Richard M ^a   Cryan, John F ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

depression; glutamate; mouse

Indexed keywords

6 (4 METHOXYPHENYL) 5 METHYL 3 (4 PYRIDINYL) ISOXAZOLO[4,5 C]PYRIDIN 4(5H) ONE HYDROCHLORIDE; AMN 082; ANTIDEPRESSANT AGENT; METABOTROPIC RECEPTOR 7; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL TEST; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; TAIL SUSPENSION TEST;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZHYDRYL COMPOUNDS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; HINDLIMB SUSPENSION; MALE; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; MOTOR ACTIVITY; PYRIDONES; RECEPTORS, METABOTROPIC GLUTAMATE; SPECIES SPECIFICITY; SWIMMING;

EID: 84874879323     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32835efc78     Document Type: Article

References (46)

1. Bahi A, Fizia K, Dietz M, Gasparini F, Flor PJ (2012). Pharmacological modulation of mGluR7 with AMN082 and MMPIP exerts specific influences on alcohol consumption and preference in rats. Addict Biol 17:235-247.
2. Berton O, Nestler EJ (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137-151.
3. Bouron A, Chatton JY (1999). Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Neuroscience 90:729-736.
4. Bradley SR, Uslaner JM, Flick RB, Lee A, Groover KM, Hutson PH (2012). The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling. Pharmacol Biochem Behav 101: 35-40.
5. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. (2011). Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9:1-16.
6. Burrows GD, Maguire KP, Norman TR (1998). Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 59 (Suppl 14):4-7.
7. Conn PJ (2003). Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann NY Acad Sci 1003:12-21.
8. Conn PJ, Pin JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
9. Crane G (1961). The psychotropic effects of cycloserine: a new use for an antibiotic. Compr Psychiatry 2:51-59.
10. Crawley JN (1999). Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835:18-26.
11. Cryan JF, O'Leary OF (2010). Neuroscience. A glutamate pathway to faster-acting antidepressants? Science 329:913-914.
12. Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA (2001). Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepi-nephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 298:651-657.
13. Cryan JF, Hoyer D, Markou A (2003). Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54: 49-58.
14. Cryan JF, Dev KK (2008). Chapter 4.4 The glutamatergic system as a potential therapeutic target for the treatment of anxiety disorders. In: Blanchard DC, Griebel GA, Blanchard RJ, David N, editors. Handbook of behavioral neuroscience. 17: Amsterdam: Elsevier. pp. 269-301.
15. De Kloet ER, Joels M, Holsboer F (2005). Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6:463-475.
16. Dinan TG (1993). A rational approach to the non-responding depressed patient. Int Clin Psychopharmacol 8:221-223.
17. Dinan TG (1994). Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry 164:365-371.
18. Fava M (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649-659.
19. Fendt M, Burki H, Imobersteg S, van der Putten H, McAllister K, Leslie JC, et al. (2010). The effect of mGlu8 deficiency in animal models of psychiatric diseases. Genes Brain Behav 9:33-44.
20. Finger BC, Dinan TG, Cryan JF (2011). High-fat diet selectively protects against the effects of chronic social stress in the mouse. Neuroscience 192:351-360.
21. Golembiowska K, Zylewska A (1999). Effect of antidepressant drugs on veratridine-evoked glutamate and aspartate release in rat prefrontal cortex. Pol J Pharmacol 51:63-70.
22. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003). The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64:1465-1475.
23. Hikichi H, Murai T, Okuda S, Maehara S, Satow A, Ise S, et al. (2010). Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4, 5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents. Eur J Pharmacol 639:106-114.
24. Holsboer F, Bender W, Benkert O, Klein HE, Schmauss M (1980). Diagnostic value of dexamethasone suppression test in depression. Lancet 2:706.
25. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE (2004). Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65:959-965.
26. Jacobson LH, Cryan JF (2007). Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behav Genet 37:171-213.
27. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH (1982). Effects of amitriptyline on serum glutamate and free tryptophan in rats. Arch Psychiatr Nervenkr 232:391-394.
28. Klak K, Palucha A, Branski P, Sowa M, Pilc A (2007). Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 32:169-172.
29. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. (2010). mTOR-department synapse formation underlines the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
30. Lucki I, O'Leary OF (2004). Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 65 (Suppl 4):11-24.
31. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr (2008). Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 69:946-958.
32. McCaslin PP, Yu XZ, Ho IK, Smith TG (1992). Amitriptyline prevents N-methyl-D-aspartate (NMDA)-induced toxicity, does not prevent NMDA-induced elevations of extracellular glutamate, but augments kainate-induced elevations of glutamate. J Neurochem 59:401-405.
33. Mitsukawa K, Mombereau C, Lotscher E, Uzunov DP, van der Putten H, Flor PJ, Cryan JF (2006). Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. Neuropsycho-pharmacology 31:1112-1122.
34. Mitsukawa K, Yamamoto R, Ofner S, Nozulak J, Pescott O, Lukic S, et al. (2005). A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci USA 102:18712-18717.
35. Niederberger E, Schmidtko A, Coste O, Marian C, Ehnert C, Geisslinger G (2006). The glutamate transporter GLAST is involved in spinal nociceptive processing. Biochem Biophys. Res Commun 346:393-399.
36. Nieuwenhuys R (1994). The neocortex. An overview of its evolutionary development, structural organization and synaptology. Anat Embryol (Berl) 190:307-337.
37. O'Connor RM, Finger BC, Flor PJ, Cryan JF (2010). Metabotropic glutamate receptor 7: at the interface of cognition and emotion. Eur J Pharmacol 639:123-131.
38. Palucha-Poniewiera A, Pilc A (2012). A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats. Behav Brain Res 238C:109-112.
39. Palucha A, Klak K, Branski P, van der Putten H, Flor PJ, Pilc A (2007). Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychophar-macology (Berl) 194:555-562.
40. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, et al. (2004). Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61:705-713.
41. Siegl S, Flor PJ, Fendt M (2008). Amygdaloid metabotropic glutamate receptor subtype 7 is involved in the acquisition of conditioned fear. Neuroreport 19:1147-1150.
42. Sukoff Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL, Zhang MY, et al. (2011). The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther 338:345-352.
43. Suzuki G, Tsukamoto N, Fushiki H, Kawagishi A, Nakamura M, Kurihara H, et al. (2007). In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. J Pharmacol Exp Ther 323:147-156.
44. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD (2005). Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144.
45. Toth I, Dietz M, Peterlik D, Huber SE, Fendt M, Neumann ID, et al. (2012). Pharmacological interference with metabotropic glutamate receptor subtype 7 but not subtype 5 differentially affects within-and between-session extinction of Pavlovian conditioned fear. Neuropharmacology 62:1619-1626.
46. Wong ML, Licinio J (2004). From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3:136-151.